The trademark application TRANSFORMING THERAPEUTICS was filed by Nektar Therapeutics, a U.S. corporation (the "Applicant"). The application was published for oppositions on September 7, 2003, and it was registered by office on February 12, 2004 without any oppositions.
The application was filed in English (French was selected as the second language).
Two renewals of the trademark were recorded, one on February 5, 2013, and the other one on June 18, 2022.
Change of name and address of the trademark registration was recorded on April 28, 2003. A transfer of the trademark registration was recorded on May 28, 2007. Change of name and address of the trademark registration was recorded on July 15, 2007. Change of name and address of the trademark registration was recorded on July 7, 2010. Change of name and address of the trademark registration was recorded on April 3, 2011. Creation of rights in rem of the trademark registration was recorded on September 10, 2012. Change of name and professional address of the trademark registration was recorded on October 1, 2018. Change of name and professional address of the trademark registration was recorded on May 16, 2019. Appointment and Replacement of representative of the trademark registration was recorded on October 29, 2019.
Goods And Services
The mark was filed in class 1 with Chemicals relating to drug performance and/or drug delivery performance for research use and manufacturing in the biotechnical, biomedical and pharmaceutical industries.
The mark was filed in class 5 with Pharmaceuticals preparations having enhanced drug performance and/or drug delivery performance for the treatment and/or prophylaxis of diseases or medical conditions such as diabetes, infections, cancers, and inflammations, or of diseases or medical conditions that affect the peripheral nerves, the adrenergic and/or cholinergic receptors, the histamine receptors, the expression and/or regulation of growth factors, the skeletal and/or smooth muscle systems, the cardiovascular system, the endocrine and/or hormone systems, the blood circulatory system, the immunological system, the synoptic and neuroeffector junctional sites, the reproductive system, the skeletal system, the autocoid system, the alimentary and/or excretory systems, and/or the central nervous system.
The mark was filed in class 42 with Technical consulting and research services and namely, providing consultation, research and development services relating to drug performance and/or drug delivery performance to others in the biotechnical, biomedical and pharmaceutical fields..